Figure 6.
Independent validation of KRAS mutations in baseline plasma from the SoFEA study. (A) Progression-free survival (PFS) in SoFEA by KRAS mutation status. HR, hazard ratio. (B) Overall survival (OS) in SoFEA by KRAS mutation status.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.